This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Lead Retrieval
November 3–5, 2025
Vienna Congress and Convention Center, Vienna, AustriaNovember 11–12, 2025 | Digital Partnering

Lynn Durham
CEO & Founder at STALICLA SA
Presenter

Profile

Lynn is a biotech entrepreneur and the Founder and CEO of STALICLA. Driven by her lifelong involvement with the ASD community, Lynn has instituted a paradigm shift in the NDD drug discovery space with the creation of the first NDD specific precision medicine platform. Her passion and determination have defined STALICLA as pioneers in NDD and, more recently, neuropsychiatric treatments. Lynn has extensive experience in business development and healthcare that she gained through successive positions working for the World Economic Forum, healthcare venture initiatives in the Lemanic area and at the Faculty of Medicine of the University of Geneva. Lynn is an inventor or co-inventor of 11 patents and the recipient of a Brain Foundation award for “outstanding leadership towards the advancement of treatments for patients Neurodevelopmental disorders”. She is a recognized thought leader in the precision psychiatry space and a reviewer for Biological Psychiatry. She is also the Founder of GATHER Foundation , a Swiss non-for-profit foundation promoting the establishment of global harmonization standards for data collection in Neurodevelopmental disorders. Lynn holds a Masters degree in Economic History and Political Science from ICP Paris, a Masters degree in Business Communication from NEOMA Business School and a post graduate Masters degree in Clinical Trials and Drug Development from the Faculty of Medicine of the University of Geneva.

Agenda Sessions

  • CNS/Neurology: STALICLA SA

    17:30

At this event